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ABSTRACT
Objective: The association between increased amniotic fluid interleukin-6 (IL-6) concentrations and
preterm labor has received increasing attention. Several research groups have evaluated this as-
sociation using commercial IL-6 kits, which .principally use the sandwich-enzyme-immunoassay
method, and were originally created to measure IL-6 in plasma, serum, or culture media. We
evaluated commercial kits for the determination of IL-6 in amniotic fluid.
Methods: Seven commercial kits were used to determine IL-6 concentrations in three amniotic
fluid samples which were obtained from patients with clinical chorioamnionitis during labor and
five from normal pregnancies at mid-trimester.
Results: Amniotic fluid IL-6 values differed significantly with some having over a 50-fold dis-
crepancy and the recovery of known IL-6 added to amniotic fluid ranged from 12 to 123%. How-
ever, by all kits we were able to identify that amniotic fluid from patients with chorioamnionitis
contained significantly higher IL-6 concentrations than those from normal mid-trimester pregnan-
cies.
Conclusion: Our data indicate that standardization of the method for measuring IL-6 in amniotic
fluid is desirable for the comparison of values from various laboratories. Infect. Dis. Obstet. Gy-
necol. 5:222-225, 1997. (C) 1997 Wiley-Liss, Inc.
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nterleukin-6 (IL-6) is a multifunctional protein
and an inducer of the acute-phase response. It is
produced by a variety of cells, and its production is
stimulated by infections. 1,2 Increasing information
has become available on the association between
amniotic fluid IL-6 concentrations and pregnancy
outcome.3-14 Several groups of investigators have
used commercial kits for the measurement of IL-6
in amniotic fluid.3’7’8’-2’14 However, these kits
were originally intended to measure IL-6 in
plasma, serum, and tissue-culture media, not in
amniotic fluid. To evaluate various kits for the
measurement of IL-6 in amniotic fluid, we used
seven commercially available kits and compared
the results of the concentrations of amniotic fluid
IL-6.
MATERIALS AND METHODS
Amniotic fluid samples were obtained during labor
using a transcervical intrauterine pressure catheter
from three women with clinical chorioamnionitis.
Clinical chorioamnionitis was diagnosed when all
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of the following were present; 1) a fever over 38C;
2) uterine tenderness; 3) fetal tachycardia; 4) ab-
sence of another clinical source of infection; and 5)
clinical diagnosis of chorioamnionitis by managing
physicians with initiation of antimicrobial .therapy.
Five amniotic fluids were collected during genetic
amniocentesis at about 17 weeks of gestation.
These amniotic fluid samples were originally col-
lected for various clinical evaluations and would
have been discarded, if not used in this investiga-
tion. Amniotic fluid samples were centrifuged
(900g for 10 rain), separated into aliquots, and
stored at-70C until analyses.
Human IL-6 assay kits were obtained from
seven commercial sources (BioSource, Camarillo,
CA; Cistron, Pine Brook, NJ; Endogen, Cam-
bridge, MA; Genzyme, Cambridge, MA; Immuno-
tcch, Westbrook, ME; PcrSeptive Diagnostics,
Cambridge, MA; and R&D Systems, Minneapolis,
MN), all of which principally use the quantitative
sandwich-enzyme-immunoassay method using 96-
well microplatcs. These kits have slight differences
not only in the ranges of standard provided but also
the assay procedures and sample volumes (Table
1). For the measurement of optical density, a mi-
croplatc reader (BioRad, Richmond, CA) was used
at the appropriate wavelengths specified by the
manufacturers.
The assay procedures were carried out according
to the instructions by the manufacturers, and all
assays were performed in duplicate. The dilution
of the samples was made based on the instructions
provided, and a pooled amniotic fluid was used as
a diluent after the fluid was heated at 100C for 10
rain for the kits prepared by Cistron, Endogcn, and
PerSeptivc Diagnostics as suggested by these
manufacturers. The range of dilutions used in am-
niotic fluid samples was between 2- and 200-fold.
Polypropylene tubes were used for the dilutions
because it was pointed out in the instructions by
two manufacturers (Immunotech and Cistron) that
polystyrene and glass may adsorb IL-6. The calcu-
lation of the final concentrations was made using
linear regression after logarithmic transformation of
optical densities. Although some instructions indi-
cated that we should use log-linear regression, the
correlation coefficients using linear regression with
a log-log scale were higher than those obtained by
log-linear regression in all kits.
Evaluation of the recovery of a known amount
of IL-6 added to an amniotic fluid sample was per-
formed by adding an aliquot of the standard solu-
tion containing the highest concentration of IL-6
supplied by each manufacturer. The volumes of
the standard solution used for this recovery test
ranged from 25 to 50% of the amount of amniotic
fluid samples in each well (300 pl). This recovery
study was done once in duplicate using three levels
of the standard. The agreement between dupli-
cates for entire assays was evaluated by calculating
the correlation coefficients between the optical
density for each duplicate after logarithmic trans-
formation. The evaluation of day-to-day variations
was not performed for each kit in the present
study.
RESULTS
The source, standard range, and characteristics of
the commercial kits are summarized in Table 1.
Some kits were more labor intensive than others.
As shown in Table 2, the IL-6 concentrations in
amniotic fluid measured in the present study var-
ied greatly depending on the kit used for the assay.
The agreement between the duplicates was gener-
ally good (Pearson correlation coefficient of over
0.980) except for one kit (BioSource) for which the
correlation coefficient was 0.923. The correlation
coefficients of standard curves generated on a log-
log scale were excellent with values over 0.950 for
five kits, whereas two kits had correlation coeffi-
cients of only 0.738 and 0.882 (Immunotech and
BioSource, respectively). The concentrations of
IL-6 in amniotic fluid samples (sample 3) differed
significantly with over a 50-fold discrepancy among
the seven kits. Furthermore, the recovery ofknown
IL-6 added to the amniotic fluid samples varied
from 12 to 123% depending on the kits used (Ta-
ble 2).
Despite these wide variations in IL-6 concen-
trations among the kits tested, all kits clearly dis-
tinguished higher amniotic fluid concentrations of
IL-6 obtained from women with clinical chorioam-
nionitis during labor compared to those from
women with normal pregnancies at mid-trimester.
The mean of three samples from patients with cho-
rioamnionitis measured by all seven kits was 20,500
ng/1 with a range between 2,300 and 116,000 ng/1,
while the mean of five samples from normal preg-
nancies was 461 ng/1 with a range between 30 and
3,100 ng/1. IL-6 in amniotic fluid was unstable,
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TABLE I. Comparisons between seven commercially available IL-6 assay kits
Standard range Diluent Wavelength Sample volume Calculation
Kit (ng/I) Incubations recommended (nm) (ll/well) recommended
BioSource 15.6-500 2 h + h + 20 min Provided 450 50 Not specified
Cistron 12.5-1,000 20 minx 4 AF (boiled) 450 100 Log-log
Endogen 39-1,050 h + 30 min x 2 AF (boiled) 450 minus 550 50 Log-linear
Genzyme 35-1,800 30 minx 2 + 15 min + 10 min Provided 450 50 Log-linear
Immunotech 3.9-1,000 2 h + 15 min Provided 404-414 100 Log-linear
PerSeptive 50-2,000 h + 30 min x 2 + 15 min AF (boiled) 450 100 Log-linear
R & D 3.13-300 2 h x 2 + 20 min Provided 450 minus 540 100 Log-log
aAmniotic fluid.
TABLE 2. IL-6 concentrations (ng/I) in amniotic fluid samples and assay performance in seven kits
Samples BioSource Cistron Endogen Genzyme Immunotech PerSeptive R & D
8,900 12,900 7,300 3,900 12,400 2,300 4,700
2 11,400 21,200 25,800 5,900 86,200 4,700 26,000
3 9,700 116,000 14,200 4,700 43,000 2,300 7,450
4 60 710 56 71 130 440 90
5 1,800 3,100 1,100 750 1,000 440 1,000
6 ND 440 ND 90 80 ND 30
7 210 ND 290 80 ND 40 140
8 60 ND 480 70 ND 30 130
Recovery (%) 69 77 85 123 III 12 95
Duplicate agreement 0.923 0.985 0.996 0.999 0.999 0.996 0.993
Linear regression 0.545 0.947 0.966 0.952 0.778 0.970 0.934
aData are calculated based on the mean of duplicates.
bNot determined due to insufficient amount of samples due to repeated freeze-thaw.
CCorrelation coefficients between duplicate optical density readings.
dCorrelation coefficients of linear regression for standard curves after both optical density and standard concentrations were log-transformed.
since the concentrations of IL-6 decreased mark-
edly once the samples had been thawed and refro-
zcn at-70C. Therefore, several dilutions of am-
niotic fluid should be included at the initial assay to
avoid additional freeze-thaw cycles which appar-
ently destroy labile IL-6. In addition, the assay pro-
cedures for each kit took a maximum of 7 h includ-
ing calculations. Therefore, the data can be re-
ported within 24 h to physicians who manage
patients.
DISCUSSION
Because of strong interest in establishing the asso-
ciation between genital tract infections and preg-
nancy outcome,-14 many investigators, using com-
mercially available kits, have sought to measure
IL-6 concentrations in amniotic fluid sam-
ples."’7,8,1-1z,14 However, it has not been well es-
tablished whether the commercially available kits
are suitable to measure IL-6 in amniotic fluid
samples, because these kits were originally created
for the measurement of IL-6 in plasma, serum, or
tissue-culture media. Our data indicate that com-
mercially available kits can be successfully used to
measure IL-6 in amniotic fluid, since it was pos-
sible to distinguish the samples with high IL-6 lev-
els from those with low IL-6 levels with all kits
used in this study.
However, the values obtained using the seven
kits in this study were quite different, indicating
that it is unreasonable to compare values obtained
using different kits in various laboratories. There
are several possible explanations for these discrep-
ancies among the kits. These include: 1) differ-
ences in the antibodies to IL-6 among kits which
may have different responses to allotropes of IL-6
produced by various tissues, as pointed out by
Bienvenu et al.lS; 2) the protein matrix in amniotic
fluid which affects antibody reactivity to IL-6 in
assay kits originally prepared for the measurement
of IL-6 in plasma, serum, or culture media; and 3)
differences in the preparation of the standard used
in each kit. No instruction stated how the concen-
trations of the standard were calibrated for the
preparation of the kits.
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In conclusion, it is essential that normal ranges
be established for IL-6 concentrations in amniotic
fluid for each kit used in each laboratory. In order
to compare the values from various laboratories, it
is desirable to standardize the method to measure
IL-6 in amniotic fluid.
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